TGFB1 and Parkinson disease: Increasing TGF-β signaling in the substantia nigra through adeno-associated virus expressing a constitutively active type I receptor significantly reduced MPTP-induced dopaminergic neurodegeneration and motor deficits, and thus, represents a potential therapy for PD.